Drug Approval | September 20, 2024
Briefs: Dr. Reddy's Laboratories and Torrent Pharmaceuticals
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Total investment incurred for setting up the new R&D Rs 250 crore
Subscribe To Our Newsletter & Stay Updated
